Literature DB >> 10603664

Epidemiological analysis of immunity to poliovirus after termination of an era of vaccination with OPV in Germany. An analysis of the German Association Against Viral Diseases (DVV).

S Franck1, R Allwinn, H F Rabenau, H W Doerr.   

Abstract

The global eradication of poliomyelitis by the year 2000 is an objective of the World Health Organization (WHO). Since 1998, after a period of 37 years of vaccination using live oral poliovirus vaccine (OPV), single use of inactivated poliovirus vaccine (IPV) has been recommended in Germany. The present epidemiological analysis shows the immunity of 3474 patients to poliovirus types 1, 2 and 3 by using a microneutralization assay. A non-age-specific evaluation of antibodies seroprevalence to poliovirus type 1 remained 81% and similarly, for poliovirus type 2 86% while the poliovirus type 3 decreased from 78% in 1990-1992 to 68% in 1997. In the important group of children aged 5-14 years, the prevalence of antibodies to type 3 decreased clearly from 74% in 1990 to 47% in 1997. The relatively favorable level of seroprevalence of antibody to type 2 in children aged 1-4 years (89%) indicates a good acceptance of vaccination programs. However, a good immunity to all 3 serotypes was not achieved by primary vaccination. The objective of a global eradication of poliomyelitis has not yet been be achieved. Great problems still exist, especially in Africa and Asia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10603664     DOI: 10.1016/s0934-8840(99)80086-3

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  5 in total

1.  Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students.

Authors:  Sabine Wicker; Holger F Rabenau; René Gottschalk; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Microbiol Immunol       Date:  2007-02-02       Impact factor: 3.402

2.  Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany.

Authors:  Holger F Rabenau; Matthias Richter; Hans Wilhelm Doerr
Journal:  Med Microbiol Immunol       Date:  2009-11-26       Impact factor: 3.402

3.  Deficiency of immunity to poliovirus type 3: a lurking danger?

Authors:  Claudia Reinheimer; Imke Friedrichs; Holger F Rabenau; Hans W Doerr
Journal:  BMC Infect Dis       Date:  2012-01-26       Impact factor: 3.090

4.  Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units.

Authors:  Sabine Diedrich; Hermann Claus; Eckart Schreier
Journal:  BMC Infect Dis       Date:  2002-02-06       Impact factor: 3.090

Review 5.  Is EU/EEA population protected from polio?

Authors:  Dre Nijsten; P Carrillo-Santisteve; A Miglietta; J Ruitenberg; P L Lopalco
Journal:  Hum Vaccin Immunother       Date:  2015-04-21       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.